The American genetic research company CELERA GENOMICS has announced the acquisition of the biotechnologies company AXYS PHARMACEUTICALS, specialised in cancerology, for the sum of $174.4 million. Carried out through an exchange of shares, the transaction represents the equivalent of $4.65 per AXYS share.